肥胖治疗市场按治疗类型、药物类别、给药途径、患者年龄层、分销管道和最终用户划分－2025-2032 年全球预测

预计到 2032 年肥胖治疗市场规模将成长至 294.6 亿美元，复合年增长率为 8.39%。

明确的临床创新方向、系统层级挑战和策略重点将重塑肥胖照护服务和相关人员的商业机会

肥胖治疗处于临床创新、患者期望变化和医疗保健政策演变的交汇点，需要细緻的策略性思维。药物治疗的进展，尤其是基于肠促胰岛素的治疗方法，正在透过提供新的​​非手术治疗方案来重塑治疗模式，这些方案正在改变护理途径、患者转诊模式和付款人关係。同时，外科手术也在不断发展，拥有更微创的技术和更完善的手术全期护理，在临床严重程度和合併症情况需要持久的解剖干预时，外科手术仍能发挥作用。

医疗保健提供者、药品开发商、医疗设备製造商和付款人必须协调这些临床进展与持续存在的挑战，包括不同人群之间获取药物的不一致、报销框架碎片化，以及原料药和给药设备供应链面临的压力。数位医疗、远端监控和患者参与平台的创新正开始填补后续护理和行为介入的空白，但要取得可衡量的成果，必须将其融入现有的护理生态系统。因此，将临床证据产生与切实可行的获取策略和跨学科伙伴关係关係相结合的利益相关人员，将最有能力影响患者治疗结果和组织绩效。

本引言重点阐述了相互关联的变革驱动因素——临床有效性、交付方式、监管途径和商业策略——并为寻求实用、循证指导的决策者设定了期望，从而为后续分析奠定了基础。接下来的叙述将分析该领域的变革力量、监管和贸易阻力、细分市场对产品和服务设计的影响，以及在建立长期韧性的同时应对短期衝击的可行建议。

不断发展的临床范式、交付方式和付款人期望正在推动肥胖治疗从偶发性干预向纵向综合护理模式的系统转变。

肥胖治疗领域正在经历一场变革性的转变，这得益于药物治疗的突破、外科手术的改进以及数位化疗法的日趋成熟。针对代谢和食慾调节路径的药物治疗已证实具有临床意义的减重效果，并具有更广泛的心臟代谢益处。这一转变正在加速整合内分泌、基层医疗、行为健康和营养服务的多学科护理模式，从而增加持续患者管理的接触点。

同时，减重手术和微创手术的创新改善了手术全期的安全性和恢復时间，为晚期疾病或难治性药物治疗患者提供了手术选择。给药方式也日趋多样化，口服和肠外给药并存，每种途径对依从性、储存和病人支持有不同的需求。随着临床技术的进步，分销管道也不断发展。零售店和专科诊所模式正在适应全通路患者病人历程，其中面对面咨询、远端医疗追踪和电子商务履约必须协调一致，以确保护理的连续性。

政策和支付方环境的调整并不均衡，一些支付方正在扩大药物治疗的覆盖范围，而另一些支付方则要求疗效可证实。这种可及性方面的差异加剧了差异，并奖励製造商开发强有力的现实世界证据和基于价值的合约模式。总体而言，该领域正在从偶发性介入转向纵向管理框架，强调持续疗效、患者体验和经济价值，并将临床创新与系统思维相结合。

预计 2025 年的贸易政策调整将对营运、定价和准入产生复合影响，因此需要采取积极主动的参与策略来增强供应链的弹性和补偿

2025年美国加征关税或贸易政策变化将产生一系列累积影响，肥胖照护生态系统的相关人员必须评估并减轻这些影响。对进口活性药物成分、给药装置或特殊医疗设备征收关税将增加依赖全球供应链的製造商的投入成本。这些成本压力可能会透过分销管道层层迭加，影响标价、返利策略以及与付款人和医疗保健提供者的谈判动态。价格变动的幅度将取决于合约结构和治疗类别内的竞争强度。

除了直接的成本影响外，关税还可能改变供应商的行为和投资计画。供应商可能会补充生产库存、实现采购多元化或投资更高的库存缓衝，以降低贸易政策波动带来的风险。此类策略倡议需要资金和时间，并可能随着产能的重新分配在短期至中期内导致供应曲折点。对于肠外治疗和一次性给药装置，无菌和监管核准限制了供应商的兼容性，因此任何中断都可能对供给能力和临床运作产生重大影响。减重护理机构可能面临设备和植入成本的增加，这会影响治疗经济性和个案选择标准。

关税导致的成本上升也将影响研发的优先顺序。企业可能需要重新评估其在研专案投资，或优先考虑那些对低风险进口产品依赖程度较低的计划。在支付者和提供者层面，成本上升可能会加强对比较有效性和长期疗效的审查，从而加速对真实世界证据和卫生经济分析的需求。从公共卫生角度来看，减少可负担医疗服务和医疗可近性的政策可能会加剧现有的差距，并对医疗保健机会有限或肥胖基准盛行率较高的人群造成不成比例的影响。因此，全面的缓解策略（例如，实现采购来源多元化、与相关人员签订合作合约、尽可能投资国内製造以及积极主动地与相关人员沟通）对于保持医疗服务的连续性和维持治疗应用的势头至关重要。

将治疗方式、药理类别、给药途径、患者群体、管道和护理环境与策略挑战联繫起来的观点

細項分析揭示了治疗方式、药理机制、给药途径、患者人口统计、分销管道和最终用户环境之间复杂的相互作用，每种相互作用都对临床实践和商业策略有着独特的影响。根据治疗类型，可分为药物治疗和外科手术，其中药物治疗又分为非处方药和处方药；外科手术则包括减肥手术、胃绕道手术和腹腔镜手术。这些差异至关重要，因为每种治疗途径都涉及不同的临床决策点、监管要求和患者教育需求，这决定了从初次咨询到长期随访，患者就诊病人历程中相关人员的类型。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• GLP-1受体促效剂广泛整合到基层医疗肥胖症通讯协定中
• 提供个人化肥胖管理方案的数位治疗平台的出现
• 越来越多地使用针对多种代谢途径的联合药物疗法来治疗肥胖症
• 扩展虚拟减重指导，整合人工智慧驱动的行为改变支持
• 增加对用于慢性体重管理介入的植入式神经刺激设备的投资
• 开发个人化基因筛检来指导针对性肥胖治疗的选择和剂量
• 生物製药公司与科技Start-Ups建立新伙伴关係，加速肥胖治疗创新进程
• 扩大付款人报销模式，涵盖远端医疗肥胖服务和远端监控解决方案

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章肥胖治疗市场（依治疗类型）

• 药物治疗
  • 非处方药
  • 处方药
• 外科手术
  • 减重手术
  • 胃绕道手术
  • 腹腔镜手术

第九章肥胖治疗市场（依药物类别）

• 食慾抑制剂
• GLP-1受体促效剂
• 脂肪酶抑制剂
• 代谢加速器

第 10 章肥胖治疗市场（依给药途径）

• 口服
• 肠外

第 11 章肥胖治疗市场（依患者年龄层）

• 成人
• 老年人
• 孩子们

第 12 章肥胖治疗市场（依通路）

• 线下零售
• 网路零售

第 13 章肥胖治疗市场（按最终用户划分）

• 医院和诊所
• 专科诊所
• 减重与健康中心

第 14 章肥胖治疗市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第 15 章肥胖治疗市场（按群体）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章肥胖治疗市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • AbbVie Inc.
  • Apollo Endosurgery, Inc.
  • AstraZeneca PLC
  • Atkins Nutritionals, Inc.
  • BTL Aesthetics
  • CH Boehringer Sohn AG & Ko. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Herbalife Ltd.
  • Johnson & Johnson Services, Inc.
  • Kellogg Company
  • Medtronic PLC
  • Merck & Co.
  • Novo Nordisk A/S
  • NutriSystem, Inc.
  • Olympus Corporation
  • Pfizer, Inc.
  • ReShape Lifesciences, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Viking Therapeutics, Inc.
  • VIVUS LLC
  • Zealand Pharma A/S

The Obesity Treatment Market is projected to grow by USD 29.46 billion at a CAGR of 8.39% by 2032.

A clear orientation to the converging clinical innovations, system-level challenges, and strategic priorities that are reshaping obesity treatment delivery and stakeholder opportunity

Obesity treatment sits at the intersection of clinical innovation, shifting patient expectations, and evolving health policy, creating a landscape that demands nuanced strategic thinking. Advances in pharmacotherapy-most notably in incretin-based therapies-have reframed treatment paradigms by offering new non-surgical options that alter care pathways, patient referral patterns, and payer interactions. At the same time, surgical interventions continue to evolve with less invasive techniques and refined perioperative care, maintaining their role where clinical severity and comorbidity profiles necessitate durable anatomical interventions.

Healthcare providers, pharmaceutical developers, device manufacturers, and payers must reconcile these clinical advances with persistent challenges: inconsistent access across demographic groups, fragmented reimbursement frameworks, and pressures on supply chains for active pharmaceutical ingredients and delivery devices. Innovations in digital health, remote monitoring, and patient engagement platforms are beginning to close gaps in follow-up care and behavioral intervention, yet they require integration into existing care ecosystems to deliver measurable outcomes. Consequently, stakeholders who align clinical evidence generation with pragmatic access strategies and cross-disciplinary partnerships will be best positioned to influence both patient outcomes and organizational performance.

This introduction frames the subsequent analysis by emphasizing the interconnected drivers of change-clinical efficacy, delivery modality, regulatory pathways, and commercial strategy-and sets expectations for decision-makers seeking pragmatic, evidence-based guidance. The narrative that follows dissects transformative forces in the field, regulatory and trade headwinds, segmentation-level implications for product and service design, and actionable recommendations to navigate near-term disruption while building long-term resilience.

Evolving clinical paradigms, delivery modalities, and payer expectations are driving a systemic shift from episodic intervention toward longitudinal integrated care models for obesity treatment

The obesity treatment landscape is undergoing transformative shifts driven by breakthroughs in pharmacotherapy, refinements in surgical practice, and the maturation of digital therapeutics. In pharmacology, therapies that harness metabolic and appetite-regulating pathways have demonstrated clinically relevant weight reductions tied to broader cardiometabolic benefits, prompting clinicians and payers to reevaluate lines of therapy and treatment sequencing. This shift is accelerating multidisciplinary care models that integrate endocrinology, primary care, behavioral health, and nutrition services, creating more touchpoints for sustained patient management.

At the same time, procedural innovation in bariatric and minimally invasive surgery has improved perioperative safety and recovery timelines, preserving the role of surgical options for patients with advanced disease or refractory responses to medical therapy. Delivery modalities are also diversifying: oral formulations and parenteral administration coexist, and each route creates distinct adherence, storage, and patient support needs. Parallel to clinical advances, distribution channels are evolving. Retail and specialty clinic models are adapting to omnichannel patient journeys where in-person consultations, telemedicine follow-ups, and e-commerce fulfillment must be coordinated to ensure continuity of care.

Policy and payer landscapes are adapting unevenly, with some payers expanding coverage for pharmacologic therapies contingent on demonstrable outcomes, while others maintain restrictive criteria. This differential access amplifies disparities and incentivizes manufacturers to develop robust real-world evidence and value-based contracting approaches. Overall, the sector is shifting from episodic interventions toward longitudinal management frameworks that blend clinical innovation with systems thinking, emphasizing sustained outcomes, patient experience, and economic value.

Projected trade policy adjustments in 2025 will create compounding operational, pricing, and access implications that necessitate proactive supply chain resilience and reimbursement engagement strategies

The introduction of additional tariffs or trade policy changes in the United States in 2025 introduces a set of cumulative effects that stakeholders across the obesity treatment ecosystem must evaluate and mitigate. Tariffs on imported active pharmaceutical ingredients, delivery devices, or specialized medical equipment would increase input costs for manufacturers that rely on global supply chains. Those cost pressures are likely to cascade through distribution channels, influencing list prices, rebate strategies, and negotiation dynamics with payers and healthcare providers. The magnitude of price transmission will vary depending on contracting structures and the competitive intensity within therapeutic categories.

Beyond immediate cost impacts, tariffs can alter supplier behavior and investment timelines. Suppliers may reshore production, diversify sourcing, or invest in higher inventory buffers to reduce exposure to trade policy volatility. Such strategic moves require capital and time and may lead to short- to medium-term supply inflection points as capacity is reallocated. For parenteral therapies and single-use delivery devices, where sterility and regulatory approvals constrain supplier interchangeability, any disruption can have outsized effects on availability and clinical operations. Facilities that perform bariatric procedures may face increased equipment and implant costs that influence procedural economics and case selection criteria.

Tariff-driven cost increases also have implications for research and development prioritization. Companies may need to reassess pipeline investments or prioritize projects with lower dependency on at-risk imports. At the payer and provider level, increased costs could intensify scrutiny around comparative effectiveness and long-term outcomes, accelerating demand for real-world evidence and health economic analyses. In public health terms, policies that reduce affordability or access could exacerbate existing disparities, disproportionately affecting populations with limited healthcare access or higher baseline prevalence of obesity. Consequently, comprehensive mitigation strategies-including sourcing diversification, collaborative contracting with payers, investment in domestic manufacturing where feasible, and proactive stakeholder communication-are essential to preserve continuity of care and maintain momentum in therapeutic adoption.

A multi-dimensional segmentation perspective connecting treatment modalities, pharmacologic classes, administration routes, patient cohorts, channels, and care settings to strategic imperatives

Segmentation analysis reveals the complex interplay among treatment modalities, pharmacologic mechanisms, administration routes, patient demographics, distribution channels, and end-user settings, each of which carries distinct implications for clinical practice and commercial strategy. Based on treatment type, the landscape includes pharmacotherapy and surgical procedures; pharmacotherapy further divides into over-the-counter drugs and prescription medications, while surgical procedures encompass bariatric surgery, gastric bypass, and laparoscopic surgery. These distinctions matter because each pathway involves different clinical decision points, regulatory requirements, and patient education needs, and they determine the types of stakeholders involved in patient journeys from initial consultation through long-term follow-up.

Based on drug class, therapeutic approaches span appetite suppressants, GLP-1 receptor agonists, lipase inhibitors, and metabolism boosters, each presenting unique efficacy, safety, and monitoring profiles that inform both prescriber behavior and payer criteria. Based on route of administration, the market includes oral and parenteral options; oral therapies offer convenience and potentially broader uptake, while parenteral agents may deliver higher efficacy or different tolerability characteristics and will require administration support and cold-chain logistics. Based on patient age group, stakeholders must address the different clinical needs and adherence challenges of adults, elderly patients, and pediatric populations, paying particular attention to dosing, comorbidity profiles, and long-term follow-up strategies.

Based on distribution channel, treatment access occurs through offline retail and online retail models; offline settings continue to play a critical role for procedural interventions and in-person clinical management, while online channels expand access for certain pharmacologic therapies and ongoing patient support. Based on end-user, services and products are delivered across hospitals and clinics, specialty clinics, and weight loss and wellness centers, each with distinct procurement practices, clinical workflows, and reimbursement environments. Integrating these segmentation lenses reveals where product design, channel strategy, and evidence generation must align to meet clinical needs and payer expectations across diverse patient cohorts and care settings.

Distinct regional regulatory, reimbursement, and cultural dynamics across the Americas, Europe Middle East Africa, and Asia Pacific require tailored access and evidence strategies

Regional dynamics vary significantly and require differentiated approaches to regulatory engagement, access strategy, and partnership development. In the Americas, regulatory pathways in North America leverage robust clinical trial infrastructure and more mature payer frameworks, producing rapid adoption cycles for high-efficacy therapies where reimbursement aligns with demonstrated outcomes. Health systems in the region are also contending with substantial unmet need and demographic heterogeneity, which creates opportunities for integrated care models and value-based contracting that tie reimbursement to sustained clinical benefit.

In Europe, the Middle East & Africa, regulatory regimes present a patchwork of approval timelines and reimbursement criteria that necessitate targeted market entry planning and local evidence generation. Several countries prioritize cost-effectiveness and comparative analyses within health technology assessment frameworks, driving the need for region-specific real-world data and economic models. In many emerging markets across these regions, infrastructure constraints and out-of-pocket payment prevalence affect the feasible adoption pathways for both pharmacologic and surgical interventions.

In the Asia-Pacific region, market heterogeneity includes advanced markets with sophisticated regulatory systems alongside rapidly developing health systems where rising prevalence and growing middle-class demand are increasing access to obesity treatments. Supply chain considerations, local manufacturing capacities, and regional regulatory harmonization efforts influence launch sequencing and commercial investments. Across all regions, cultural perceptions of obesity, provider training, and the availability of multidisciplinary care teams shape adoption curves and long-term treatment paradigms, making localized stakeholder engagement and tailored evidence packages essential for successful program implementation.

Competitive advantage will accrue to organizations that combine differentiated clinical outcomes evidence, integrated care partnerships, and adaptable commercial and supply chain capabilities

Competitive dynamics are increasingly defined by the ability to demonstrate differentiated clinical outcomes, optimize delivery and support services, and engage payers with persuasive health economic evidence. Leading biopharmaceutical developers are investing in outcome studies and patient support programs to address adherence, persistence, and long-term safety monitoring, while device and procedural innovators emphasize improved perioperative pathways and enhanced recovery protocols to reduce complications and total episode costs. Partnerships between drug developers and specialty clinics or digital health providers are emerging as a way to integrate behavioral interventions, remote monitoring, and adherence support into commercial offerings, increasing the perceived value for payers and patients alike.

Strategic capabilities that separate successful organizations from peers include robust real-world evidence generation, flexible manufacturing and supply chain arrangements, and sophisticated payer engagement models that can support value-based reimbursement. Companies that invest in education for clinicians and allied health professionals, while simultaneously scaling patient engagement tools, stand to accelerate adoption and improve outcomes. Additionally, cross-sector collaboration-spanning pharmaceuticals, device manufacturers, health systems, and technology providers-creates opportunities to deliver end-to-end solutions that address both the biological and behavioral components of obesity, positioning organizations to capture more of the continuum of care.

Practical and coordinated actions for leaders to fortify supply chains, build value-based evidence, and expand integrated patient delivery models to safeguard access and accelerate adoption

Industry leaders should pursue a coordinated set of actions that align clinical evidence generation, supply chain resilience, and payer engagement to preserve access and sustain innovation. First, diversify sourcing and invest in regional manufacturing or strategic supplier partnerships to mitigate exposure to trade policy disruptions and to reduce lead-time risk for critical inputs such as active pharmaceutical ingredients and single-use devices. Complement supply-side measures with inventory optimization and contractual clauses that allow for flexibility during periods of geopolitical uncertainty.

Second, prioritize the generation of rigorous real-world evidence and health economic models that demonstrate long-term value across relevant patient populations and care settings. Use pragmatic trials, registries, and payer data partnerships to quantify outcomes that matter to payers, including reductions in comorbidity burden, hospital utilization, and total cost of care. Third, innovate in patient support and delivery models: integrate digital therapeutics, remote monitoring, and multidisciplinary care coordination to improve adherence and persistence, while reducing the burden on brick-and-mortar facilities.

Fourth, engage proactively with payers and health technology assessment bodies to design reimbursement pathways that reflect longitudinal benefits rather than short-term cost metrics. Consider pilots for outcomes-based contracts that align pricing to sustained clinical endpoints. Fifth, tailor regional market entry and commercialization strategies to local regulatory requirements, cultural contexts, and infrastructure realities, using local partnerships to expedite uptake. Finally, invest in workforce development by equipping clinicians, nurses, and allied health professionals with the training and tools needed to deliver complex chronic-disease management effectively. Together, these actions will strengthen organizational resilience and help sustain patient access during periods of disruption.

A layered research methodology blending primary stakeholder interviews, targeted secondary intelligence, and rigorous triangulation to ensure actionable and defensible insights

The research approach combines a layered methodology designed to triangulate insights from diverse and credible sources. The primary research component includes structured interviews with clinicians, payers, procurement leaders, and patient advocacy representatives to capture firsthand perspectives on clinical decision-making, reimbursement constraints, and access barriers. Supplementing these interviews, expert advisory panels provide thematic validation and scenario testing to stress-test strategic assumptions and to surface emerging operational risks.

Secondary research draws on peer-reviewed clinical literature, regulatory filings, public policy documents, and published guidance from relevant health authorities to construct the clinical and regulatory context. Commercial intelligence is gathered from company disclosures, trial registries, and patent landscapes to map competitive positioning and innovation trajectories. Where appropriate, real-world datasets and claims analyses are used to assess utilization patterns and care pathways, while methodological safeguards-such as data cleaning, outlier analysis, and triangulation-ensure analytical rigor.

Analytical techniques include thematic synthesis for qualitative inputs, comparative regulatory analysis, and health economic modeling frameworks to interpret cost and outcome relationships qualitatively. Limitations of the methodology are acknowledged: stakeholder perspectives may evolve rapidly with new clinical data or policy changes, and access to certain proprietary datasets can constrain granularity. To mitigate these limitations, iterative updates and targeted follow-up interviews are recommended following major regulatory or clinical developments.

A concise synthesis emphasizing the strategic imperative to combine clinical evidence, operational resilience, and payer engagement to enhance outcomes and sustain access

The obesity treatment ecosystem is at an inflection point where clinical innovation, supply chain realities, and payer expectations converge to redefine care pathways. Stakeholders that proactively align evidence generation with pragmatic access strategies and resilient operational planning will capture disproportionate value while improving patient outcomes. The interplay between pharmacologic advances and procedural care underscores the need for integrated, multidisciplinary approaches that account for patient heterogeneity and long-term management needs.

Managing near-term risks-such as trade policy shifts, supply chain constraints, and reimbursement variability-requires deliberate actions that include sourcing diversification, targeted real-world evidence development, and close payer collaboration. Simultaneously, investments in digital care models and patient support mechanisms can enhance adherence and extend the benefits of clinical advances to broader patient populations. In sum, the path forward favors organizations that balance scientific rigor with operational agility and who partner across the care continuum to deliver measurable, sustainable improvements in patient health.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Widespread integration of GLP-1 receptor agonists into primary care obesity protocols
• 5.2. Emergence of digital therapeutics platforms offering personalized obesity management programs
• 5.3. Increasing use of combination pharmacotherapy targeting multiple metabolic pathways for obesity
• 5.4. Expansion of virtual weight loss coaching integrating AI driven behavioral change support
• 5.5. Rising investment in implantable neurostimulation devices for chronic weight management interventions
• 5.6. Growth of personalized genetic screening to guide targeted obesity therapy selection and dosing
• 5.7. Emerging partnerships between biopharma and tech startups to accelerate obesity treatment innovation pipelines
• 5.8. Expansion of insurer reimbursement models covering telehealth obesity services and remote monitoring solutions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obesity Treatment Market, by Treatment Type

• 8.1. Pharmacotherapy
  • 8.1.1. Over-The-Counter Drugs
  • 8.1.2. Prescription Medications
• 8.2. Surgical Procedures
  • 8.2.1. Bariatric Surgery
  • 8.2.2. Gastric Bypass
  • 8.2.3. Laparoscopic Surgery

9. Obesity Treatment Market, by Drug Class

• 9.1. Appetite Suppressants
• 9.2. GLP-1 Receptor Agonists
• 9.3. Lipase Inhibitors
• 9.4. Metabolism Boosters

10. Obesity Treatment Market, by Route of Administration

• 10.1. Oral
• 10.2. Parenteral

11. Obesity Treatment Market, by Patient Age Group

• 11.1. Adults
• 11.2. Elderly
• 11.3. Pediatric

12. Obesity Treatment Market, by Distribution Channel

• 12.1. Offline Retail
• 12.2. Online Retail

13. Obesity Treatment Market, by End-User

• 13.1. Hospitals & Clinics
• 13.2. Specialty Clinics
• 13.3. Weight Loss & Wellness Centers

14. Obesity Treatment Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Obesity Treatment Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Obesity Treatment Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. AbbVie Inc.
  • 17.3.2. Apollo Endosurgery, Inc.
  • 17.3.3. AstraZeneca PLC
  • 17.3.4. Atkins Nutritionals, Inc.
  • 17.3.5. BTL Aesthetics
  • 17.3.6. C.H. Boehringer Sohn AG & Ko. KG
  • 17.3.7. Eli Lilly and Company
  • 17.3.8. F. Hoffmann-La Roche Ltd
  • 17.3.9. GlaxoSmithKline plc.
  • 17.3.10. Herbalife Ltd.
  • 17.3.11. Johnson & Johnson Services, Inc.
  • 17.3.12. Kellogg Company
  • 17.3.13. Medtronic PLC
  • 17.3.14. Merck & Co.
  • 17.3.15. Novo Nordisk A/S
  • 17.3.16. NutriSystem, Inc.
  • 17.3.17. Olympus Corporation
  • 17.3.18. Pfizer, Inc.
  • 17.3.19. ReShape Lifesciences, Inc.
  • 17.3.20. Rhythm Pharmaceuticals, Inc.
  • 17.3.21. Sanofi SA
  • 17.3.22. Takeda Pharmaceutical Company Limited
  • 17.3.23. Viking Therapeutics, Inc.
  • 17.3.24. VIVUS LLC
  • 17.3.25. Zealand Pharma A/S

LIST OF FIGURES

• FIGURE 1. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. OBESITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. OBESITY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. OBESITY TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL OBESITY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 202. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 244. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 260. AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 261. AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 262. AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 275. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 299. ASEAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 300. ASEAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 304. ASEAN OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 305. ASEAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 306. ASEAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 307. ASEAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 308. ASEAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 309. ASEAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 310. ASEAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 311. ASEAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 312. ASEAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 313. GCC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 314. GCC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 315. GCC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 316. GCC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 317. GCC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 318. GCC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 319. GCC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 320. GCC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 321. GCC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 322. GCC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 323. GCC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 324. GCC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 325. GCC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 326. GCC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 327. GCC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 328. GCC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 329. GCC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 330. GCC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)

TABL